Literature DB >> 11757631

Anti-inflammatory effect of adenovirus-mediated IkappaBalpha overexpression in respiratory epithelial cells.

G Y Park1, S Le, K H Park, C T Le, Y W Kim, S K Han, Y S Shim, C G Yoo.   

Abstract

Many studies into basic biological characteristics of inflammation and tissue injury have implicated pro-inflammatory cytokine-mediated tissue injury in the pathogenesis of inflammatory lung diseases. Because transcription of most proinflammatory cytokines is dependent on the activation of nuclear factor (NF)-kappaB, NF-kappaB could be a good potential target to suppress the cytokine cascade. Cytokine-induced activation of NF-kappaB requires phosphorylation and subsequent degradation of IkappaBa. Therefore, the blocking NF-kappaB activation by IkappaBalpha could inhibit the pro-inflammatory cytokine-induced tissue injury. To evaluate whether blocking of NF-kappaB activation shows an anti-inflammatory effect, this study investigated the effect of adenovirus-mediated overexpression of IkappaBalpha super-repressor (IkappaBalpha-SR) on the pro-inflammatory cytokine expression in respiratory epithelial cells. The transduction efficiency of adenovirus was >90% in both A549 and NCI-H157 cells. Ad5IkappaBalpha-SR-transduced cells expressed high levels of IkappaBalpha-SR, which was resistant to tumour necrosis factor (TNF)-alpha-induced degradation. Adenovirus-mediated overexpression of IkappaBalpha-SR blocked cytokine-induced nuclear translocation of p65 and NF-kappaB deoxyribonucleic acid binding activity without affecting total cellular expression level of NF-kappaB. Ad5IkappaBalpha-SR transduction suppressed cytokine-induced interleukin-8 and TNF-alpha expressions at both ribonucleic acid and protein levels. These results suggest that blocking the nuclear factor-kappaB pathway by adenovirus-mediated overexpression of IkappaBalpha-super-repressor shows an effective anti-inflammatory effect in respiratory epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11757631     DOI: 10.1183/09031936.01.00099801

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Temporal activation of NF-kappaB regulates an interferon-independent innate antiviral response against cytoplasmic RNA viruses.

Authors:  Santanu Bose; Niladri Kar; Ratan Maitra; Joseph A DiDonato; Amiya K Banerjee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

2.  Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.

Authors:  Kyoung-Hee Lee; Jiyeong Jeong; Chul-Gyu Yoo
Journal:  J Biol Chem       Date:  2013-10-01       Impact factor: 5.157

3.  Interleukin-10 inhibits elevated chemokine interleukin-8 and regulated on activation normal T cell expressed and secreted production in cystic fibrosis bronchial epithelial cells by targeting the I(k)B kinase alpha/beta complex.

Authors:  Olivier Tabary; Céline Muselet; Sandie Escotte; Frank Antonicelli; Dominique Hubert; Daniel Dusser; Jacky Jacquot
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

Review 4.  Science review: redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for hypoxia-inducible factor-1alpha.

Authors:  John J Haddad
Journal:  Crit Care       Date:  2002-10-14       Impact factor: 9.097

5.  A model of the onset of the senescence associated secretory phenotype after DNA damage induced senescence.

Authors:  Patrick Meyer; Pallab Maity; Andre Burkovski; Julian Schwab; Christoph Müssel; Karmveer Singh; Filipa F Ferreira; Linda Krug; Harald J Maier; Meinhard Wlaschek; Thomas Wirth; Hans A Kestler; Karin Scharffetter-Kochanek
Journal:  PLoS Comput Biol       Date:  2017-12-04       Impact factor: 4.475

Review 6.  Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for nuclear factor-kappaB.

Authors:  John J Haddad
Journal:  Crit Care       Date:  2002-10-14       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.